Informed Consent Form Translation: FDA Requirements & Audit Risks
Clinical trials increasingly involve participants who speak a wide range of languages. This makes informed consent form translation a critical part of study conduct.
Under 21 CFR Part 50, there are clear regulatory standards for informed consent. When participants aren’t able to understand the consent information presented to them, the ethical foundation of informed consent—and the regulations designed to protect participants—may be compromised. As such, any clinical trials involving participants with limited English proficiency must incorporate informed consent form translation into their workflow.
Errors in translation and failure to document translation practices can lead to audit exposure and issues in clinical trial translation compliance. In this article, we’ll take a closer look at FDA informed consent translation requirements and walk you through some best practices for compliance.
Why Informed Consent Form Translation Is a Regulatory Obligation
Clinical trials in the United States must comply with 21 CFR Part 50, which requires that prospective participants receive information in language they can understand before agreeing to participate.
The ethical basis for informed consent is straightforward: Participants must be able to evaluate the risks and benefits of participating in a trial before making their decision. When individuals do not speak English fluently, informed consent form translation enables them to arrive at a well-founded decision about whether or not to participate. Unsurprisingly, studies have shown that insufficient informed consent form translation can be an obstacle to participation for people who don’t speak English. Ultimately, multilingual consent forms make consent meaningful, rather than just procedural.
There are two common approaches to translated informed consent FDA expectations: full translation of the informed consent document or the use of a short-form consent process. The short-form method allows oral presentation of the full consent information with a translated summary document, though it must meet strict ICF translation guidelines.
An institutional review board (IRB) plays a central role in the translation process. Under IRB translation requirements, translated documents must be reviewed and approved to confirm that the translated consent accurately reflects the original text and meets clinical trial translation compliance standards. Maintaining a clear documentation trail, strong version control, and consistent translation practices supports audit readiness during any regulatory inspection.
FDA and IRB Expectations for Translated Informed Consent Forms
The FDA informed consent translation requirements and IRB translation requirements establish clear expectations for how translated consent materials ought to be prepared. By meeting the following expectations, you can maintain clinical trial translation compliance and strengthen audit readiness during inspections:
– Accuracy and completeness: Translations must faithfully reflect the meaning of the original document without omissions, simplifications or added interpretation. For multilingual consent forms in clinical trials, the FDA expects LEP participants to receive the same information—risks, benefits, procedures, rights, etc.—as English-speaking participants.
– Documentation of translator qualifications: Organizations should maintain records showing that translators are qualified to perform informed consent form translation. This often includes documentation of language proficiency, relevant experience with medical or regulatory texts, and familiarity with informed consent form translation guidelines.
– Review and approval requirements: The IRB overseeing the study should typically review and approve any translated consent forms before they were used.
– Certification statements: Studies commonly include a signed certification confirming that the translation is complete and accurate. These statements help create a clear documentation trail which is useful for audits or any other regulatory inspection.
– Version control requirements: Each translated document should correspond precisely to a specific version of the source informed consent form. Strong version control prevents outdated or inconsistent materials from being used during participant enrollment.
– IRB submission documentation: When submitting translated materials for review, sponsors or research sites typically provide the translated consent form, the English source document, and supporting translation documentation.
Common Audit Risks in ICF Translation
Clinical trials that involve multilingual participants face unique audit risks due to FDA informed consent form translation requirements. Below are a few examples of errors that commonly occur in the ICF translation process that you should be aware of:
- Incomplete or inconsistent translations: Participants with LEP need to be able to access all of the information that their English-speaking counterparts have access to. If translations don’t cover all of the risks, benefits, procedures, etc., they are considered incomplete and are not fit for use until these errors have been fixed
- Lack of documentation trail: It’s important to keep a record of all your informed consent form translation procedures. Without sufficient documentation to show details like translator/interpreter qualifications, review records, certification statements, and so on, organizations may struggle to demonstrate clinical trial translation compliance.
- Version control failures: Translation errors often arise when a translated document does not match the most recently approved version of the source consent form. Poor version control can result in participants receiving outdated information, which creates serious audit readiness concerns and may trigger questions from the relevant IRB.
- Inadequate linguistic validation in complex studies: In highly complex clinical trials, literal translation alone may not be enough to make sure participants fully understand certain medical concepts. A careful linguistic review establishes that multilingual consent forms in clinical trials explain risks and procedures in clear, understandable language while still following approved ICF translation guidelines.
Best Practices for Clinical Trial Translation Compliance
To make sure your team is providing LEP participants with thorough informed consent form translations and meeting compliance with FDA and IRB requirements, here are a few best practices you can implement into your translation workflow:
Work with life sciences-qualified linguists: Working with linguists who specialize in translating and interpreting materials for life sciences organizations ensures that you’re working with people who are familiar with your unique compliance needs. Qualified linguists won’t have to spend time getting up to speed with new procedures or terminology, as they’ve already worked on similar projects.
Implement dual review process: A second independent linguistic review helps catch terminology issues, omissions, or inconsistencies that might otherwise be missed. Dual review also strengthens the accuracy of multilingual consent forms in clinical trials and supports stronger clinical trial language compliance.
Maintain traceable documentation: Documentation is critical for audit readiness. Keep an organized record of things like translator qualifications, certification statements, etc., so you have them at the ready during a regulatory inspection.
Align translation SOPs with sponsor SOPs: Translation procedures should align with the broader standard operating procedures used by sponsors and research sites. This alignment helps ensure that translated informed consent FDA expectations are met consistently across all study documentation
Maintain version tracking and change logs: Be careful to make sure that you’re translating the most up-to-date version of any and all documentation.
Archive all translation-related records: Just because you needed a document translated a long time ago, doesn’t mean you should get rid of your records of it. Store old records in an archive that you can come back to in case you need them even after the required retention period is over.
Preparing for Regulatory Inspection
Preparing for a regulatory inspection means making sure your informed consent translation process is clearly documented and that you can show how translated consent forms were produced, reviewed, and maintained.
Inspectors will want to take a close look at the paper trail left during the translation process—they may request the source and target text, records of translator qualifications, signed certifications confirming that a translation is complete, and more. Inspectors will look at these documents to make sure that a qualified linguist was assigned to the task, that the translation fully covers the scope of the source text, and that the translation was adequately reviewed before approval.
Be sure to retain all records related to the informed consent form translation process for the full period required by study and regulatory retention policies—for FDA-regulated clinical trials, investigators must retain records (including documentation showing that informed consent was obtained) for at least two years after either the date the marketing application for the drug/device is approved for the investigated indication, or if no application is filed or approved, two years after the investigation is discontinued and the FDA is notified.
Frequently Asked Questions
The FDA does not explicitly require “certified translations” for informed consent forms, but it does require translations to be complete and accurate. In practice, organizations usually maintain record of translator qualifications and certification statements to demonstrate compliance with translation requirements during regulatory inspection.
Short-form consent is permitted only when the participant does not speak English and a full translation is not available. Under 21 CFR Part 50, the consent information must still be presented orally in the participant’s language, and the short-form document and English consent form must be reviewed and approved by the IRB.
Sponsors and research sites should keep a detailed record of the translation procedure for at least two years. Such documentation includes translator qualifications, certification statements, review and approval records, and any records showing version control between the English source and translated target versions.
Translations must be updated whenever the English source text is updated to ensure consistency in the information presented to English-speaking participants and LEP participants.
Conclusion
By implementing the best practices laid out in this blog post, researchers can rest easy knowing that all of their trial participants are making well-informed decisions about their involvement. Informed consent form translation helps researchers meet both ethical and regulatory obligations.
Working closely with a language service provider who’s familiar with standard procedures for life sciences organizations is key to audit readiness. At Avantpage Life Sciences, we can translate your informed consent forms into more than 150 different languages, keeping a thorough paper trail at every step of the way. Download our compliance checklist today or contact us to learn more.